When: Price at $1,186

Then: Hold existing position; do not chase

HOLD with hardened risk controls: stop below 50 SMA ($1,157), scale-in tranches at 25-30% max, explicit invalidation conditions

• June 29 high of $1,229.93 represents resistance, not accumulation - stock failed to break out despite multiple catalysts including 50% revenue growth and antitrust victory
• Forward PEG of 0.47 is circular reasoning using consensus estimates already embedded in price; TTM PEG of 1.64 is the actual market valuation
• MACD at 3.26 with signal line at 5.92 and histogram at -2.66 (widening) represents meaningful loss of upside thrust, not noise
• Momentum decelerated from 40.27 on July 8 to 3.26; ATR expanded to 42.11 from 36 a month ago indicating widening daily ranges
• 50 SMA at $1,157 defended once on August 4 - one data point is not a generational floor
• August 5 candle moved $78 in a single session ($1,138 to $1,216) - illustrates ATR-driven volatility risk
• 200 SMA sits at $1,031; a break below 50 SMA with $42 ATR means fast, violent move to 200 SMA
• Trader's $2 hard stop at $1,098 on $1,100 entry is insufficient given $42 ATR - needs to be below 50 SMA at $1,157
• IRA drug pricing 20% haircut on Medicare-eligible volume represents multi-billion dollar revenue hit that collapses multiple at 40x earnings
• Pfizer's berobenatide Phase 3 data (2028-2030) is forward-looking multiple compression risk, not just a launch threat
• Beta of 0.506 is backward-looking; forward risk profile for single-franchise GLP-1 concentration is meaningfully higher
• Scale-in levels at $1,031-$1,050 should be 25-30% of target position, not 50% - add into confirmed support, not hope

→ vs aggressive: Claims 'priced in' analysis is lazy - actually the most important signal: 50% revenue growth, raised guidance, antitrust win, Medicare expansion, and stock went nowhere. That is market voting no confidence, not accumulation

→ vs aggressive: Forward PEG of 0.47 uses consensus estimates already embedded in price - circular reasoning. TTM PEG of 1.64 is the real market valuation based on actual earnings

→ vs aggressive: MACD crossovers in secular uptrends 'resolve higher' is the same dangerous logic used in 2021 before regime change - data shows negative, widening histogram at -2.66

→ vs aggressive: 'Scale in hard at $1,100-$1,125' is conviction in name only - that behavior destroys risk-adjusted returns when ATR is $42 and 50 SMA has one successful defense

→ vs aggressive: IRA drug pricing 'manageable because still profitable' ignores that 40x earnings stocks need growth narrative intact, not just positive margins

→ vs aggressive: Record S&P highs as evidence rate sensitivity doesn't matter confuses correlation with causation - AI capex concentration masks underlying pressure on long-duration assets

→ vs neutral: HOLD designation is correct but needs explicit de-risking protocol with specific invalidation conditions, not just wait-and-see positioning

HOLD with technical conditions - maintain existing position, add at $1,100-$1,125 zone with stop at $1,090 and 33-40% sizing per tranche

• Hold designation is correct given extraordinary intact fundamentals (50% revenue growth, 102% ROE, antitrust win, Medicare expansion, 2027 retatrutide catalyst)
• Forward PEG of 0.47 is circular reasoning; TTM PEG of 1.64 reflects actual market pricing for delivered performance
• MACD at 3.26 versus signal at 5.92, histogram at minus 2.66 and widening, with momentum decelerating from 40.27 on July 8 - not noise
• Stock rallied approximately 30% off 200 SMA between June and late July; flat reaction to beat-and-raise is institutional accumulation during digestion phase, not distribution
• Current two-dollar stop ($1,098) is theater not discipline on a $42 ATR stock with 60-80 dollar daily ranges - will get hunted
• Proposed stop for new tranches at $1,090 provides 10-35 dollars of room, consistent with ATR environment
• Position sizing: 33-40% per tranche balances meaningful participation against overexposure if 50 SMA fails
• Keep one-third of capital in reserve for opportunistic adds or averaging down
• Clean invalidation framework: close below 50 SMA at $1,157 on volume = medium-term thesis broken; 200 SMA at $1,031 fails on retest = long-term thesis broken
• No arbitrary MACD countdown or automatic exit on hot CPI - setup either holds its structure or does not

→ vs aggressive: Forward PEG at 0.47 is circular reasoning using optimistic forward earnings assumption already baked into price; MACD deterioration signals are being dismissed as noise when the histogram at minus 2.66 and widening is a concrete deterioration signal, not survivorship-bias-safe confirmation

→ vs aggressive: Two-dollar stop placement on a stock with $42 ATR is functionally not a stop - will get wicked out by routine volatility

→ vs conservative: Flat reaction to beat-and-raise after a 30% run is consistent with institutional accumulation and digestion, not bearish distribution - reading tape to confirm priors

→ vs conservative: MACD recovery within 10 sessions is arbitrary with no analytical basis; making every macro event an exit trigger is reactive trading that gets whipsawed

→ vs conservative: 25-30% position sizing per tranche is so defensive the trader will likely miss the entry when price rockets off support without them